HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
Top Cited Papers
- 1 July 2006
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 10 (1), 25-38
- https://doi.org/10.1016/j.ccr.2006.05.023
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Modelling glandular epithelial cancers in three-dimensional culturesNature Reviews Cancer, 2005
- IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer PatientsJournal of Clinical Oncology, 2005
- Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?Trends in Molecular Medicine, 2004
- Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane culturesMethods, 2003
- Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cellsExperimental Cell Research, 2003
- The Role of Apoptosis in Creating and Maintaining Luminal Space within Normal and Oncogene-Expressing Mammary AciniCell, 2002
- Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthCancer Cell, 2002
- Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapyThe EMBO Journal, 2002
- c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor FunctionJournal of Biological Chemistry, 1999